Paradigm shifts with the opening of IDH inhibition era

A new era in the management of mIDH diffuse glioma has begun with the arrival of IDH inhibitors. How do they work? How do they impact clinical practice? This video is here to answer your questions!

This Plenary entitled Paradigm shifts with the opening of IDH inhibition era has taken place at the MDT masterclass in Barcelona in April 2025. 

Chaired by M. Weller and I. Mellinghoff, the agenda was the following: 

- Targeting a key driver in mIDH diffuse gliomas - M. Weller (SW) 10min

- Insights & learnings from the INDIGO study and its follow-up - P. Wen (USA) 20min

- Clinical implication - A 3-dimension approach over the world - I. Mellinghoff (USA), R. Ruda (IT) & Y. Narita (JPN) 15min

- Future perspectives and opportunities of treatment sequences - E. Galanis (USA), M. Geurts (NL) & T. Cloughesy (USA) 15min